(HealthDay News) — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those ...

New York, New York-- (Newsfile Corp. - February 15, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and ...

Medications that have transformed the treatment of obesity may also help people drink less alcohol, according to new government-funded research.

At the recent SEC meeting for Endocrinology and Metabolism held on 13th January 2025, the expert panel reviewed the ...

Dr. Philip A. Chan joined GoLocal to discuss the new wave of weight loss drugs and their implications for fighting obesity as well as their implications for other applications like kidney disease and ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...